S
ESPR

SignatureFD’s Esperion Therapeutics ESPR Stock Holding History

SignatureFD’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7K Buy
1,487
+1,016
+216% +$2.84K ﹤0.01% 2878
2026
Q1 		$1.29K Buy
471
+29
+7% +$92 ﹤0.01% 3157
2025
Q4 		$1.64K Buy
+442
New +$1.43K ﹤0.01% 3022
2024
Q3 		– Sell
-342
Closed -$759 – 3265
2024
Q2 		$759 Buy
+342
New +$805 ﹤0.01% 2940
2023
Q2 		– Sell
-1,169
Closed -$1.86K – 3274
2023
Q1 		$1.86K Sell
1,169
-1,716
-59% -$8.86K ﹤0.01% 2825
2022
Q4 		$18K Sell
2,885
-413
-13% -$2.95K ﹤0.01% 1860
2022
Q3 		$22K Buy
3,298
+403
+14% +$2.77K ﹤0.01% 1686
2022
Q2 		$18K Buy
2,895
+2,518
+668% +$14.3K ﹤0.01% 1824
2022
Q1 		$2K Sell
377
-507
-57% -$2.17K ﹤0.01% 2794
2021
Q4 		$4K Buy
884
+788
+821% +$6.31K ﹤0.01% 2475
2021
Q3 		$1K Buy
+96
New +$1.4K ﹤0.01% 2812
2020
Q3 		– Sell
-19
Closed -$1K – 2641
2020
Q2 		$1K Buy
+19
New +$795 ﹤0.01% 2291
2019
Q1 		– Sell
-1
Closed – – 1992
2018
Q4 		$0 Buy
+1
New +$48 ﹤0.01% 1969

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

SignatureFD's ESPR Position: Q2 2026 in Review

SignatureFD increased its Esperion Therapeutics (ESPR) stake by 216% in Q2 2026, buying an estimated $2.84K and bringing the position to 1,487 shares worth $4.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

SignatureFD first reported a position in ESPR in Q4 2018 and has held it in 13 quarters since. The position peaked at $22K in Q3 2022. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • SignatureFD held 1,487 shares of Esperion Therapeutics worth $4.7K as of Q2 2026.
  • SignatureFD bought 1,016 Esperion Therapeutics shares in Q2 2026, an estimated $2.84K.
  • Esperion Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2878 holding.
  • SignatureFD first reported a position in Esperion Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • SignatureFD's Esperion Therapeutics position peaked at $22K in Q3 2022.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.